Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model

Abstract

ReuseUnless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version -refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website. TakedownIf you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. Accepted ManuscriptTitle: Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model

Chitosan Ameliorates Candida auris Virulence in a Galleria mellonella Infection Model

“…Two isolates of C. auris (one non-Agg isolate, NCPF 8973, and one Agg isolate, NCPF 8978) were selected for the Galleria mellonella killing assay as previously described ( 14 ). G. mellonella larvae were infected with these two isolates in the presence and absence of chitosan in a similar manner to that described elsewhere ( 45 – 47 ). In short, 10 sixth instar G. mellonella larvae (Livefoods Direct Ltd, Sheffield, UK) weighing between 200 and 300 mg were selected for each test group.…”

Pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and -resistant enterococci in vitro and in vivo of a Galleria mellonella larval infection model

“…The Galleria mellonella larva infection model has been previously used for the research of the virulence of numerous human pathogens and the efficacy of the antimicrobial agents (32–34). G. mellonella has also been effectively employed to test the effects of rifampicin combination therapy against enterococcal infections in the past(35). When compared with mammalian models, G. mellonella is cheaper to obtain and free of ethical constraints (36).…”

Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing

“…Combination treatment demonstrated higher protection of larvae post-infection in comparison with antibiotic monotherapy. In particular, rifampicin in combination with tigecycline or vancomycin significantly enhanced survival [71].…”